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Abstract
Magnetic resonance imaging (MRI) can measure the
effects of therapies targeting the tumor vasculature
and has demonstrated that vascular-damaging agents
(VDA) induce acute vascular shutdown in tumors in
human and animal models. However, at subtherapeutic
doses, blood flow may recover before the induction of
significant levels of necrosis. We present the relation-
ship between changes in MRI biomarkers and tumor
necrosis. Multiple MRI measurements were taken at
4.7 T in athymic rats (n = 24) bearing 1.94 ± 0.2–cm3
subcutaneous Hras5 tumors (ATCC 41000) before and
24 hours after clinically relevant doses of the VDA,
ZD6126 (0–10 mg/kg, i.v.). We measured effective
transverse relaxation rate (R2*), initial area under the
gadolinium concentration–time curve (IAUGC60/150),
equivalent enhancing fractions (EHF60/150), time con-
stant (K trans), proportion of hypoperfused voxels as
estimated from fit failures in K trans analysis, and signal
intensity (SI) in T2-weighted MRI (T2W). ZD6126 treat-
ment induced > 90% dose-dependent tumor necrosis
at 10 mg/kg; correspondingly, SI changes were evi-
dent from T2W MRI. Although R2* did not correlate,
other MRI biomarkers significantly correlated with
necrosis at doses of >_ 5 mg/kg ZD6126. These data on
Hras5 tumors suggest that the quantification of hypo-
perfused voxels might provide a useful biomarker of
tumor necrosis.
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Introduction
The growth of solid tumors requires a functional vascular
network to supply oxygen and nutrients and to removewaste
products [1–3]. In contrast to antiangiogenic approaches,
vascular-damaging agents (VDAs) such as ZD6126 selec-
tively aim to destroy existing tumor blood vessels, leaving
normal blood vessels relatively unaffected [4]. ZD6126 is
a phosphate prodrug that, in vivo, is rapidly converted by
phosphatases in serum to ZD6126 phenol. ZD6126 phenol
binds to tubulin, inhibiting microtubule assembly, thereby
destabilizing the intracellular microtubule network. Disruption
of the microtubule network selectively affects tumor blood
vessels because immature proliferating endothelial cells are
thought to rely, at least in part, on a microtubule cytoskeleton to
maintain cell shape and function [5]. In contrast, mature endo-
thelial cells have a well-developed actin cytoskeleton that
provides structural support [6]. Therefore, ZD6126 treatment
leads to selective rounding up of immature endothelial cells,
disrupting the endothelial cell monolayer lining the tumor vas-
culature, reducing blood flow [7], and inducing blood vessel
occlusion, with subsequent tumor cell death due to nutrient
deprivation [8]. In preclinical models, VDAs have been shown
to induce extensive necrosis throughout the tumor, usually
within 24 hours [9–12]. Characteristically, a rim of viable tumor
survives treatment, as these cells are sustained by blood
vessels in surrounding nontumor tissues, which remain un-
affected by VDA treatment. For a description of VDAs and the
principal actions of ZD6126, see Siemann et al. [13]. Due to
rapid tumor regrowth from this viable rim, the antitumor activity
of single doses of VDAs, as assessed by changes in tumor size,
usually appears modest despite the induction of extensive
tumor cell necrosis [9]. Therefore, monitoring tumor size alone
is unlikely to provide a reliable biomarker for the underlying
biologic activity or antitumor effects of single doses of VDAs.
Consequently, other methods to measure the antivascular
effects of VDAs, such as pharmacodynamic magnetic reso-
nance imaging (MRI) biomarkers, have been investigated both
clinically and preclinically [14–17]. In contrast to single doses,
multiple doses of VDAs, or a combination with therapeutic
approaches targeting the surviving tumor rim, have demon-
strated significant tumor growth delay or tumor shrinkage in
preclinical models [5,9,18,19].
Dynamic contrast-enhanced (DCE) MRI permits an indirect
and noninvasive measurement of tumor function in both human
and animal models. Different approaches can be taken toward
the analysis of DCE-MRI data. For example, initial area under
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the gadolinium contrast agent concentration– time curve
(IAUGC) data from a region of interest (ROI) or from single
voxels can be used as a biomarker of tumor physiology. More
complex compartmental modeling has attempted to derive
other biomarkers of tumor physiology, such as K trans [the
volume transfer constant for a contrast agent into the extra-
vascular extracellular space (EES)], Ve (the volume of the
EES), and kep (the rate constant for the backflux from the
EES to the intravascular space) [20–22]. For an extensive
review of different MR approaches for measuring tumor
angiogenesis and its pharmacological modulation, see
Leach et al. [20], drup-Link et al. [23], Jeswani and Padhani
[24], and Kiessling et al. [25].
DCE-MRI has been used to measure the effects of VDAs
on humans and has shown decreases in both tumor K trans
and IAUGC [15,16]. For example, after a single dose of
ZD6126, Evelhoch et al. [15] showed an acute decrease in
the IAUGC, with only partial recovery at later times. Similarly,
Galbraith et al. [16] demonstrated that a single dose of
combretastatin A4 phosphate (CA4P) caused a reduction
in IAUGC showing partial recovery over 24 hours and that
multiple CA4P doses in one patient maintained a reduction
in K trans from baseline. Similar changes in DCE-MRI bio-
markers have also been described in either ZD6126-treated
or CA4P-treated animal xenograft tumor models. However,
Evelhoch et al. [15], Galbraith et al. [16], and Maxwell et al.
[26] were unable to clearly correlate drug-induced changes
in tumor DCE-MRI biomarkers with induced tumor necrosis.
Robinson et al. [17] demonstrated a dose-dependent re-
duction in tumor IAUGC and R2* 24 hours after ZD6126 ad-
ministration, which was associated with increased tumor
necrosis. Emerging MR techniques that measure vascular
maturation [27], size [28–30], and function [27,31] are also
of interest to the research fields of vascular physiology and
therapeutic modulation.
MRI uniquely permits the acquisition of multiple contrasts
in one sitting. However, the underlying biologic process
dictates that contrast in humans is often not accessible and
that, if biopsies are available, they are limited in their fre-
quency and tumoral location. The current study was under-
taken to explore the relationships, at clinically relevant
doses, between ZD6126-induced tumor necrosis and MRI
biomarkers in a tumor xenograft model to identify potential
acute biomarkers for ZD6126-induced tumor necrosis in
patients. The Hras5 transformed mouse NIH 3T3 fibroblast
tumor line was selected because it has a reproducibly low
level of background tumor necrosis. MRI protocol included
multislice T2-weighted MRI (T2W), R2*, enhancing fraction
(EHF), IAUGC, and K trans measurements, all performed
within the same experiment. This imaging protocol exploited
those imaging biomarkers most used in phase I clinical
investigations of abdominal tumors exposed to vascular-
modulating therapeutic regimes [15,16,32] and included
more investigational biomarkers. In addition, multislice
hematoxylin–eosin (H&E) histology was used to measure
tumor necrosis. In parallel studies, it was shown that a single
dose of 2.5 to 12.5 mg/kg ZD6126 in rats produced plasma
levels of ZD6126 phenol broadly equivalent to those
achieved in humans at single doses of 40 to 112 mg/m2
(data not presented here). Therefore, in this study, we fo-
cused on exploring the effects of ZD6126 within this clinically
relevant dose range (2.5–10 mg/kg).
Materials and Methods
Rats were given food and water ad libitum. All animal proce-
dures were performed in full compliance with licenses issued
under the UK Animals (Scientific Procedures) Act following
local ethical committee review and with United Kingdom
Coordinating Committee on Cancer Research guidelines.
Tumor Development and Scheduling
Male athymic rats (V 200 g) bearing subcutaneous hind-
flank Hras5 tumors were established (mean tumor volume ±
SEM, 1.94 ± 0.2 cm3). The Hras5 cell line was isolated from
mouse NIH 3T3 fibroblasts transfected with pT24C3 plasmid
containing a mutant, the transforming form of the HRAS1
gene (ATCC 41000) [8].
Three groups of 15 animals implanted at 10-day inter-
vals. The animals were randomized by tumor size 3 days
before their first imaging session, and 10 animals per implant
group were recruited into the imaging study. Animals under-
went two imaging sessions: 24 hours before and 24 hours
after ZD6126 (2.5, 5, 7.5, or 10 mg/kg) or vehicle ad-
ministration intravenously. ZD6126 was prepared as de-
scribed elsewhere [5].
Animal Preparation
Restraint during MRI was achieved by anesthesia with
an isoflurane/air mixture (1.5% isoflurane at 2 l/min air).
Each animal was prepared and imaged in a purpose-built
polymethylmethacrylate-lidded bed. The tail was warmed, a
vein was catheterized using a 26-gauge catheter, and a can-
nula containing gadopentetate dimeglumine (0.3 mmol/kg
Gd-DTPA, ‘‘Magnevist’’; Schering,Berlin,Germany) andhepa-
rinized saline was connected. Forepaws were then con-
nected to ‘‘wrap-around’’ silver electrodes connected to a
respiration device and an electrocardiogram monitoring de-
vice (SA Instruments, Stony Brook, NY). Once in the mag-
net, the temperature was monitored and maintained at
37jC by a home-built thermocouple system and a flow of
warm air.
MRI and Tumor Histology
MRI was carried out in a 400-mm-diameter horizontal-
bore 4.7-T magnet (Varian, Palo Alto, CA) using a 63-mm
quadrature birdcage transmit/receive radiofrequency coil.
Each animal underwent a fast gradient-echo coronal pilot
scan to confirm positioning within the radiofrequency coil. A
fast spin-echo (SE) sagittal sequence then provided ana-
tomic images to determine the coordinates of tumor slices.
Except in multigradient echo (MGRE) and rapid acquisition
with relaxation enhancement (RARE) scans, subsequent
acquisitions employed a field of view of 80  60 mm with
four contiguous 2-mm sagittal slices through the tumor
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interleaved with a fifth transverse 2-mm slice through dorsal
spinal muscle. Firstly, R2* measurements were taken using a
four-slice MGRE technique (matrix = 128  64; average =
12; repetition time TR = 11 milliseconds; echo time TE = 5, 10,
15, 20, 25, 30, 35, and 40 milliseconds). Secondly, a fat-
suppressed fast four-slice RARE sequence provided a
heavily T2-weighted image to permit good tumor delineation
and qualitative morphologic interpretation (matrix = 128 
128; echo train length = 8; echo spacing = 10 milliseconds;
average = 2; TR = 1 second; effective TE = 40 milliseconds).
Thirdly, a five-slice SE sequence (TR = 0.5, 2, and 10 sec-
onds; matrix = 128  64; average = 2; TE = 9 milliseconds)
provided a precontrast T1 map. Finally, a precontrast set of
five five-slice T1-weighted SE images (TR = 0.12 seconds;
matrix = 128  64; average = 2; TE = 9 milliseconds) was
acquired followed by the commencement of DCE-MRI scan
in the same five-slice locations for a further 10 minutes in
which the manual injection of contrast agent over 3 sec-
onds occurred.
After the second imaging time point at 24 hours after
ZD6126 treatment, each animal was killed using a technique
specified in Schedule 1 of the UK Animals (Scientific Proce-
dures) Act 1986, and the tumor was excised and placed in
formalin fixative for H&E processing and necrosis measure-
ments. For each tumor, necrosis was determined from five
tumor slices with 200 mmof separation using operator-guided
image analysis software. The area of necrosis within the
whole-tumor section was determined visually, and the pro-
portion of necrotic nonviable tumor over the whole section
was calculated using image analysis software written for
the Zeiss KS400 version 3.0 image analyzer (Carl Zeiss
Vission GmbH, Hallbergmoos, Germany). For each group,
the mean percentage of necrosis and standard error were
calculated. The results are presented as the mean tumor
necrosis (%) for all tumors (five slices per each tumor) in
each treatment group.
In the current investigation, 30 animals were entered,
and 24 complete data sets were analyzable. Data were
excluded if they did not satisfy predetermined inclusion
criteria, including injection failure, poor tumor implant as
determined from T2W image, or experimental/acquisition
failure. There was no detectable change in muscle values
after ZD6126 treatment.
MRI Data Analysis
Whole-tumor ROI were manually drawn over T2-weighted
high-spatial-resolution images and used to segment the
tumor and to extract the biomarkers described below.
Tumor R2* (sec
1) maps were generated for each slice,
using all eight gradient-echo images and fitting an exponen-
tial model voxelwise [17]. For each slice, R2* was determined
for an ROI encompassing the whole tumor, but excluding
muscle and skin.R2*, the effective transverse relaxation rate,
is the sum of the homogeneous component R2 and the
inhomogeneous component R2V. An increase in R2* may
arise from an increase in the intracellular compartment tissue
content of paramagnetic iron species, primarily deoxyhemo-
globin (dHb), consistent with: 1) a reduction in perfusion; 2)
an increase in metabolic activity uncoupled to a vascular
response (increase in the concentration of intracellular dHb);
3) congestion of erythrocytes after ZD6126 thrombosis
resulting in erythrocyte deoxygenation (increase in intra-
cellular dHb); or 4) intratumoral bleeding, all of which can
ultimately affect the overall heterogeneity of the tissue under
investigation. A decrease in R2* may arise from a decrease
in R2V, reflecting an increase in tissue water associated
with edema and/or necrosis or vessel collapse.
T1 values were measured immediately before the injec-
tion of contrast agent using multi-TR T1W scan. Changes in
T1 values during DCE-MRI acquisition were estimated from
changes in signal intensity (SI) obtained for each voxel, given
baseline T1 values. From T1W images, voxelwise IAUGC,
and EHF60/150 and K
trans biomarkers were calculated. For
each tumor, a median IAUGC of the whole tumor was deter-
mined over the first 60 and 150 seconds (mM sec) from the
four imaging slices. Tumor IAUGC voxel values greater
than the muscle median IAUGC were defined as enhancing
voxels. EHF is the fraction of tumor voxels defined as, thus,
enhancing. Group values were then presented as the mean
of individual animals’ voxel medians. Muscle ROI were
drawn on T1W precontrast agent scans.
K trans (sec1) was obtained by pharmacokinetic modeling
using the model of Tofts and Kermode (Eq. (1)), which was
implemented using a software written in this laboratory. The
Nelder-Mead Simplex Method was used when fitting the
data using a program developed in-house using MATLAB
software (MathWorks, Natick, MA) [33]. Concentrations of
Gd-DTPA were derived using the known relaxivity of gado-
pentetate from the time course of T1 values in plasma and
tumor determined from DCE-MRI series. Vascular input
function (VIF) was modeled by:
½Gdplasmat ¼ D ½a1 expðm1tÞ þ a2 expðm2tÞ; ð1Þ
where D = 0. 26388 mmol/kg, the bolus dose of Gd-DTPA; a1
andm1 reflect the equilibration of Gd-DTPA between plasma
and extracellular space; a2 and m2 represent the kidney
clearance of Gd-DTPA; and (a1 + a2)
1 (l/kg) represents
the plasma volume of the rat per unit of body weight. The
values a1 = 17, a2 = 7, m1 = 0.03, and m2 = 0.001 were
obtained from unpublished studies in athymic rats in this
laboratory and agree with earlier reports [34].
Not all voxels provide valid values of K trans. For some
voxels, the Nelder-Mead Simplex Method fit fails to con-
verge, whereas some give values that would be classified
as nonphysiological (K trans < 0 or > 0.01 sec1). These fit
failures were set to zero, and the data, both excluding and
including fit failures, are presented.
Mean whole-tumor values from the four imaging slices for
each tumor from each animal were calculated before and
after treatment. Significance testing used one-tailed un-
paired Student’s t test: the biomarker compared was the
change in IAUGC, K trans, or EHF in the ZD6126-treated
group compared to that in the vehicle-treated group. Data
are presented as mean ± SEM, unless otherwise stated.
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Results
ZD6126 Induces Extensive Tumor Necrosis
in Hras5 Xenografts in Nude Rats
Tumor volume, as determined by caliper measurements,
was 1.94 ± 0.2 cm3 before ZD6126 treatment. Significant
tumor growth inhibition would not be anticipated after only
one dose of ZD6126 at any dose [9]. Consistent with
previous reports [8], ZD6126 induced extensive (> 90%)
central tumor necrosis in the Hras5 model 24 hours after
drug treatment, with viable tumor cells observed only at the
periphery of the tumor at a dose of 10 mg/kg (Figures 1l and
2a). In contrast, untreated tumors showed a low background
level of necrosis (Figures 1i and 2a). A dose response was
observed, with a significant increase in tumor necrosis at
ZD6126 doses ofz 5.0 mg/kg (Figure 2a), with some regions
of heterogeneous staining on H&E sections at intermediate
doses of 5.0 and 7.5 mg/kg (Figure 1k).
T2W Tumor Images Reveal Varied Tumor Heterogeneity
in Ascending Doses of ZD6126
Figure 1 illustrates T2W data for four tumors from dif-
ferent animals before (Figure 1, a–d ) and 24 hours after
(Figure 1, e–h) a single dose of 0, 5, 7.5, or 10 mg/kg
ZD6126. Changes in T2W SI are seen following ZD6126
treatment. However, a heterogeneous response in signal
changes over the whole tumor is seen after different doses
of ZD6126. For example, a hypointense core is seen in the
tumor of animals treated with 10 mg/kg, corresponding to a
region of necrosis (Figure 1h, l, and n for corresponding
tumor H&E sections from the same animals). In contrast, the
animals treated with 5.0 or 7.5 mg/kg ZD6126 showed a
heterogeneous T2W SI within the tumor core, consistent with
the heterogeneity seen on H&E sections (Figure 1, f, g, j, k,
andm, for corresponding tumor H&E sections from the same
animals). Such changes in T2 SI may reflect different necrotic
states (e.g., acute or chronic necrosis and/or hypoxia or
varied types of tissue integrity as a result of different doses
of ZD6126). Interestingly, ‘‘penumbral’’-like regions are evi-
dent in K trans maps illustrated in Figure 3. This observation
appeared consistent within the different dose groups (data
not shown).
R2* Values Significantly Decrease 24 Hours
after ZD6126 Treatment
Figure 2b illustrates changes in whole-tumor mean R2*
values 24 hours before and after treatment with vehicle or
ZD6126. Compared with vehicle-treated controls, a significant
Figure 1. T2W images of Hras5 tumors before and after ZD6126 treatment. T2W tumor images 24 hours before (a–d) or 24 hours after (e–h) treatment with
vehicle (a and e) or ZD6126 at 5.0 mg/kg (b and f), 7.5 mg/kg (c and g), or 10.0 mg/kg (d and h). Visual inspection revealed a broadly homogenous signal across
the tumor mass in pretreated and vehicle-treated animals. After ZD6126 treatment, heterogeneity in SI within tumors was seen (f –h). One hour after the second
MRI, tumors were excised. Representative H&E–stained tumor sections are shown for animals’ treatment with vehicle (i) or ZD6126 at a dose of 5.0 mg/kg (j),
7.5 mg/kg (k and m), or 10.0 mg/kg (l and n), respectively. Necrotic (N) and viable (V) regions of the tumor are identified. Vehicle-treated animals showed a low level
of spontaneous tumor necrosis (i), whereas higher doses of ZD6126 resulted in extensive central tumor necrosis with smaller regions of viable tissue toward the
periphery (k and l). After 10 mg/kg ZD6126, there is a clear boundary between the necrotic core and the viable tumor rim (n), whereas at lower doses, there was
evidence of heterogeneity across the tumor (m).
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decrease in R2* was observed after ZD6126 treatment at
doses of > 5 mg/kg. This observation agrees with earlier
reports showing a decrease in R2* after administration [17].
EHF and IAUGC60/150 Changes after
ZD6126 Administration
Figure 2c summarizes the mean change in tumor
IAUGC60 in each treatment group 24 hours after ZD6126
administration. Tumor IAUGC60 24 hours after 5, 7.5, and
10 mg/kg ZD6126 administration was lower than those in
vehicle-treated controls (changes in pre to post ZD6126 in
each group: 52 ± 13%, P = .02; 70 ± 25%, P = .05; 77 ±
19%, P = .1). Although the decrease after 10 mg/kg ZD6126
did not reach statistical significance, this treatment group
had a mean IAUGC value before drug treatment lower
(IAUGC60 = 4.22 ± 1.23 sec
1) than those of vehicle controls
(IAUGC60 = 5.82 ± 0.87 sec
1) or other ZD6126 treatment
groups (IAUGC60 range = 7.67 ± 0.33 to 9.04 ± 1.19 sec
1),
which may have limited the capability to detect a statisti-
cally significant decrease due to VDA therapy. Analysis of
IAUGC150 produced similar results (data not shown).
Tumor IAUGC values greater than the muscle median
IAUGCwere defined as highly enhancing pixels. This thresh-
old was not chosen to compare muscle and tumor, but rather
to identify the proportion of the tumor that enhanced signifi-
cantly (EHF). Figure 2d summarizes the mean changes in
EHF60 observed 24 hours after ZD6126 treatment. After 5,
7.5, or 10 mg/kg ZD6126, there was a reduction in EHF60
compared with vehicle-treated controls (changes in pre to
post ZD6126 in each group: 35 ± 2.8%, P = .05; 61 ±
19%, P = .058; 63 ± 9%, P = .002). Although the animals
treated with 7.5 mg/kg ZD6126 did not reach statistical
significance, there was a strong trend indicating a decrease.
Analysis of EHF150 showed similar results (data not shown).
Analysis of K trans and K trans Fit Failures Illustrates Spatial
Changes across the Tumor after ZD6126 Treatment
Figure 3 summarizes the mean K trans results from the
whole tumor, including and excluding zeroed K trans fit failures
before and after ZD6126 administration. Vessel occlusion
will drastically compromise the inflow of contrast agent and
will result in poorly enhancing regions. Where K trans is < 0 or
> 0.01 sec1, voxels were classified as fit failures. Separate
analyses were carried out either: 1) excluding fit-failure
voxels, or 2) setting the value of fit-failure voxels to zero
and including these in the analysis. The decrease in mean
tumor K trans is significantly greater than that in controls
24 hours after treatment with either 5 or 7.5 mg/kg ZD6126
whether the analysis included or excluded fit failures (Fig-
ure 3, b and c). The failure to detect significant changes
24 hours after 10 mg/kg ZD6126 may be associated with
very few voxels fitting after treatment, but those that did
largely skewed the data. Overall, such results suggest that
the perfusion status of the rim was also affected by ZD6126
treatment. Nevertheless, H&E results indicated that the
rim contained viable tumor cells (Figure 1, i– l ).
K trans maps illustrated the effects of ZD6126 across
whole Hras5 tumors (Figure 3a). Vehicle-treated and pre–
ZD6126-treatment tumors showed voxels with low K trans
values with small regions where K trans has failed to fit (dark
blue) into the core. The latter may correspond to areas of
background (non–drug-induced) tumor necrosis, which
have been observed, albeit at a low level, in the Hras5 tumor
model [9]. After 5, 7.5, and 10 mg/kg ZD6126, the number of
fitted K trans voxels in the tumor decreased until, in some
examples, < 35% of tumor voxels had K trans values that
satisfied inclusion criteria (Figure 4). As the dose of ZD6126
increased, fitted K trans voxels were more limited to the rim
of the tumor, with fit failures becoming more prevalent in
core regions (Figure 3a). At intermediate does of ZD6126,
Figure 2. Analysis of necrosis and MRI biomarkers in Hras5 tumors following
ZD6126 treatment. (a) Necrosis (mean ± SEM; %) was assessed in H&E–
stained sections. ZD6126 at doses of z 5.0 mg/kg produced significant
increases in tumor necrosis 24 hours after treatment. Whole-tumor R2*
(mean ± SEM; msec1), IAUGC60 (mean ± SEM; mmol/sec), and EHF
(mean ± SEM) are shown in (b) – (d), respectively. Pretreatment (open bars)
and posttreatment (hatched bars) values are shown for each dose group.
*P < .05, **P < .01; one-tailed unpaired t-test compared with vehicle.
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qualitative observations recognized a distinct penumbral
region between necrotic and viable tumor regions discern-
able on T2W images and H&E slides. Similarly, K
trans maps
suggested that these regions, although poorly perfused,
were not lacking functional vascularity and maintaining a
viable microenvironment (as determined by the viable rim
from H&E slides) and that these poorly perfused regions
may even extend to the rim of the Hras5 tumor 24 hours
after ZD6126 treatment. Thus, even though fitted voxels in
the viable rim of the tumor retain a degree of contrast agent
flux into the EES within a given volume, there is a signifi-
cant decrease in K trans of the tumor periphery after 5 and
7.5 mg/kg (Figure 3, b and c).
Figure 4 shows the extent of necrosis and the proportion
of voxels that were classified as K trans fit failures within each
treatment group before and after ZD6126 treatment. This
analysis confirmed the qualitative assessment ofK trans maps
in Figure 3a. Indeed, before ZD6126 administration and
at zero and low doses, few or no voxels could not be fitted
with the K trans algorithm, suggesting that there was signifi-
cant contrast agent flux within the tumor. In contrast, after
ZD6126 administration at doses of z 5 mg/kg, the number of
voxels failing to fit greatly increased. Overlaying the degree
Figure 3. K trans in Hras5 tumors following ZD6126 treatment. (a) Single-slice K trans maps are illustrated 24 hours before and 24 hours after ZD6126 administration.
K trans maps illustrate characteristic VDA effects. In both pretreatment and vehicle-treated tumors, there are some regions of low K trans, possibly corresponding with
spontaneous necrosis. In contrast, 24 hours after treatment with ZD6126, the number of fitted K trans values in the tumors became progressively lower until < 50% of
tumor voxel values fitted the model. Whole-tumor K trans measurements (mean ± SEM; sec1) before (open columns) or after (hatched columns) treatment are
shown either including (b) or excluding (c) zero fit-failure values. *P < .05, one-tailed unpaired t-test compared with vehicle.
Figure 4. K trans fit failures in the Hras-5 tumor following ZD6126 treatment.
The proportion (mean ± SEM; %) of voxels that failed to fit the Tofts and
Kermode model was calculated before (open columns) and after (hatched
columns) ZD6126 treatment. Mean tumor necrosis is also plotted for
reference (p). In pretreated tumors, the proportion of voxels failing to fit to
the model was low, which suggests that the Hras5 tumor is well perfused with
contrast agent. However, following ZD6126 treatment at doses of z 5 mg/kg,
the proportion of fit failures increases markedly, indicating inaccessibility for
the contrast agent.
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of necrosis on this plot illustrates the relationship between
histology measure and that using DCE-MRI.
Finally, ZD6126-induced changes in MRI measurements
taken 24 hours after drug treatment were related to the
percentage of tumor necrosis on an animal-by-animal basis.
R2* showed a poor correlation with the degree of necrosis
(R2 < 0.1, P > .1). K
trans fit failures, EHF60/150, IAUGC 60/150,
and K trans, including fit failures set to zero, all displayed a
significant correlation with tumor necrosis, with the latter
being largely affected by the fit failures being set to zero
(K trans fit failures: R2 = 0.69, P < .001; EHF60/150: R2 = 0.61,
P < .001; IAUGC60/150:R2 = 0.32, P < .002; K
trans including fit
failures: R2 = 0.545, P < .001). Figure 5 illustrates the
correlation between K trans fit failures and tumor necrosis.
Discussion
Acute events associated with VDA therapy include tumor
and endothelial cell apoptosis, vascular collapse and throm-
bus formation, tumor hypoxia, and fluctuations in extra-
cellular pH and oxygenation. Subsequent events may
include vascular remodeling, tumor and endothelial cellular
ischemia and necrosis, hemorrhage, and interstitial fluid
pressure changes [5,9,35–38]. Although DCE-MRI has
been utilized in clinical studies to monitor the effects of
VDAs on the tumor vasculature, there has been little work
to date to assess other clinically important biologic endpoints
such as drug-induced tumor cell necrosis and hypoxia in
these patients. In addition, there has been little preclinical
evidence correlating VDA-induced changes in tumor MRI
biomarkers with tumor necrosis at clinically relevant drug
exposure levels.
In this study, we have measured multiple noninvasive
MRI biomarkers (T2W, R2*, IAUGC60/150, EHF60/150, and
K trans) in Hras5 tumors in nude rats 24 hours before and
after treatment with ZD6126. We looked for correlations
between these imaging endpoints and ZD6126-induced
tumor necrosis 24 hours after treatment. We selected the
Hras5 tumor model for these studies as it has been reported
to have a low fraction of background necrosis in untreated
animals, even in established tumors [8,9]. In this study,
background necrosis was < 10%, confirming earlier reports.
Doses of ZD6126 that werez 5.0 mg/kg produced significant
increases in tumor necrosis, although 2.5 mg/kg ZD6126 had
no significant effect. The marked difference between the
2.5-mg/kg and the 5.0-mg/kg dose groups suggests that
the antitumor effects of ZD6126 may have a very steep dose
response, or perhaps a threshold dose, below which tumor
necrosis is not induced [8,16]. More detailed studies within
the dose range 2.5 to 5.0 mg/kg are required to investigate
this further.
Clinical studies investigating ZD6126 as a single agent
once every 3 weeks have shown over the dose range studied
(5–112 mg/m2) that plasma ZD6126 phenol levels gen-
erally increased in a linear fashion, reaching an AUC of
3894 ng hr/ml at 112 mg/m2 [39,40]. In parallel pharmaco-
kinetic studies, we have shown that doses of up to 10 mg/kg
produced a similar plasma exposure of ZD6126 phenol in
nude rats [41], supporting the concept that the dose range
examined in these studies is clinically relevant.
In this study, T2W images were acquired primarily to
provide tumor delineation for R2* and DCE-MRI measure-
ments. Although it is accepted that T2W SI can depend on
many factors, these rapidly acquired and mapping indepen-
dent images of endogenous T2 of Hras5 tumors showed a
qualitative difference 24 hours after treatment with ZD6126.
Images presented from a previous study illustrate a degree
of heterogeneity in the T2W images of the tumor after CA4P
administration [42], but not to the degree observed in the
present experimental conditions. Additionally, in the present
study, heterogeneous penumbral areas were apparent on
both T2W and H&E images, particularly at intermediate
doses, possibly representing viable—but morphologically
appearing as—hypoxic areas of tumor. However, immuno-
histologic confirmation of this would require further studies
(e.g., employing a probe specific for hypoxic conditions) [43].
The whole-tumor R2* data in the Hras5 model showed a
significant decrease 24 hours after z 5 mg/kg ZD6126,
compared with controls. Robinson et al. [17] hypothesized
that R2* would increase after ZD6126 therapy as a response
to a relative increase in dHb under hypoxic conditions as a
result of reduced tumor perfusion. However, that study found
that R2* decreased 24 hours after ZD6126 treatment in two
tumor models. A further study demonstrated that R2* in-
creased shortly after ZD6126 dosing (within 35 minutes),
consistent with the original hypothesis, but confirmed that
R2* significantly decreased 24 hours later [44]. The biologic
process(es) underlying the paradoxical decrease in R2* is
unknown, but may involve denaturation of dHb within ne-
crotic tumor tissues [44]. Nevertheless, this parameter rep-
resented the weakest correlation with necrosis.
IAUGC is an MRI biomarker that has been commonly
applied in both preclinical and clinical DCE-MRI examina-
tions. Although measurements of tumor IAUGC have the
Figure 5. A strong and significant correlation between fit failures and tumor
necrosis in the Hras5 tumor model. The proportion of fit failures (%) and
tumor necrosis 24 hours after vehicle or ZD6126 treatment was calculated on
an animal-by-animal basis (n = 24).
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advantage of being relatively robust and straightforward to
calculate, this biomarker has a complex link to underlying
tissue physiology and contrast agent kinetics. Nevertheless,
IAUGC data can be a precedent indicator to more complex
modeling results. Indeed, some literature has presented a
positive correlation between IAUGC and the more complexly
derived K trans values in colorectal liver metastases in
humans [45]. In agreement, the current IAUGC and K trans
show a strong and significant correlation at baseline (R2 =
0.91, P > .001; data not presented). In the present study, we
have demonstrated significant decreases in IAUGC60/150
following ZD6126. Evelhoch et al. [15] have performed
DCE-MRI measurements on mice bearing murine C38 tu-
mors immediately before and 24 hours after ZD6126 admin-
istration. Extensive necrosis was observed 24 hours after
ZD6126 administration, and this was associated with a re-
duction in the median tumor IAUGC. However, the ZD6126
doses used in these studies would be expected to produce
plasma ZD6126 phenol levels substantially higher than those
yet achieved in the clinic [5,8,39,40]. Two studies have
investigated DCE-MRI changes after single doses of CA4P
in rats bearing P22 carcinosarcomas at 1, 6, or 24 hours
after drug administration [16,26]. Together, these studies
demonstrated a prolonged reduction in IAUGC at a high
CA4P dose, but with full or partial recovery after 24 hours at
more clinically relevant doses.
EHF is a ratio measure using the median muscle IAUGC
signal change as a threshold for tumor signal changes [17].
Using muscle or normal tissue as a reference can permit a
subject-controlled calculation of IAUGC without the require-
ment for vascular input function. In the current study, IAUGC
from the muscle was not significantly different either day to
day, irrespective of treatment, or between animals. At doses
of z 5 mg/kg ZD6126, there were significant decreases in
EHF60/150 in Hras5 tumors. However, although the group
treated with 7.5 mg/kg did not reach statistical significance
(P = .058), the data obtained from each animal suggest a
trend to decrease 24 hours after treatment. In an earlier
study, Robinson et al. [17] demonstrated that ZD6126 in-
duced a dose-dependent decrease in EHF in the GH3
prolactinoma tumor model in Wistar-Furth rats, which ap-
peared to correlate with increased tumor necrosis 24 hours
after ZD6126 treatment. Compared with the study reported
here, higher doses of ZD6126 (z 25 mg/kg) were necessary
to demonstrate statistically significant increases in tumor
necrosis and decreases in EHF. At a lower dose (12.5 mg/
kg), IAUGC was reduced, but only in restricted areas of the
tumor. Pharmacokinetic studies used to determine the rela-
tionship between ZD6126 dosing and plasma ZD6126 phe-
nol levels were not reported in these earlier studies, so it is
uncertain whether the doses used were clinically relevant
[17]. In addition, the GH3 model has higher and more vari-
able levels of background tumor necrosis when compared
with Hras5, perhaps necessitating higher ZD6126 doses to
demonstrate statistically significant changes both in ne-
crosis and IAUGC. Alternatively, the intrinsic sensitivity of
the tumor vasculature to the effects of VDAs may have some
level of animal strain or tumor model dependency [36].
Nonetheless, previous work has demonstrated consistent
antitumor effects of ZD6126 in a histologically diverse panel
of tumor xenografts [9].
Quantitative pharmacokinetic modeling techniques can
be applied to changes in contrast agent concentrations in a
tissue or pathology of interest. Using pharmacokinetic mod-
eling, vascular kinetic biomarkers associated with underlying
physiological processes can be derived and monitored in
response to treatments. The K trans data presented here were
derived from the Tofts and Kermode model using a set of in-
house modeled VIF parameters. In the current study, the
mean K trans for the whole Hras5 tumor was significantly
reduced 24 hours after treatment with doses of 5 and
7.5 mg/kg ZD6126. Furthermore, when only fitted voxels
(i.e., those that were not set to zero) were evaluated, treat-
ment effects remained. Earlier results have described the
retention of a perfused and histologically viable rim of tumor
as a characteristic response to VDAs. This phenomenon is
thought to be due to the diffusion of oxygen and nutrients
from adjacent vasculature within neighboring nontumor tis-
sues. Nevertheless, the current results suggest that not
only does ZD6126 cause massive central necrosis but also
causes a prolonged disturbance of contrast flux of the tumor
rim because H&E histology shows a rim occupied by viable
tumor cells, but MRI data suggest that this region is func-
tionally poorly perfused, even 24 hours after drug treatment.
In support of this interpretation, Prise et al. [37] showed that
following treatment with a clinically relevant dose of CA4P,
blood flow was shut down across the whole tumor, including
the rim. Blood flow gradually returned, recovering more
quickly in the rim compared with central regions, but reaching
pretreatment levels only 48 to 96 hours after drug dosing.
In the present study, the final R2* measurement across
the whole tumor did not correlate well with necrosis. Indeed,
R2* has been shown to both increase and decrease after
VDA treatment, possibly reflecting both vascular effects and
underlying pathological changes within the tumor [17,44].
Furthermore, R2* alone may not be able to differentiate, for
example, between a phase of deoxygenation or an under-
lying hemorrhagic pool resulting from loss of tissue integrity.
IAUGC is a relatively simple biomarker that has been
used in the clinic as an early measure of therapeutic effects
on tumor vasculature for both VDA and antiangiogenic
therapies [15,16,46]. By using an internal reference, the
EHF measure takes into account a degree of systemic
change associated with contrast agent delivery. In the pres-
ent study, we have shown a good correlation between tumor
necrosis and EHF. Thus, these very poorly perfused values
appear to closely match with the degree of necrosis induced.
Further analysis may permit the resolution of regions asso-
ciated with drug-induced hypoxia. If a suitable reference
tissue could be identified within the imaging plane of the
tumor, EHF measurement may be applicable in certain
clinical situations.
K trans, excluding fit failures set to zero, showed no corre-
lation with tumor necrosis. This is most likely because this
measurement principally determines K trans at the viable
tumor rim because nonfitting K trans voxels are associated
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with necrosis in the tumor core and have been excluded from
this measurement. Different factors can affect the success of
a fitting algorithm. However, in the current experiments,
pretreatment groups show a mean 2.2% fit failure across
the whole sampled tumor. The proportion of voxels that failed
to fit using the Nelder-Mead Simplex Method algorithm
showed the strongest and most significant correlation with
tumor necrosis. This provides preclinical support for the
suggestion of Galbraith et al. [16], who proposed that non-
enhancing pixels after VDA therapy might represent areas of
tumor necrosis.
Sagittal MRI planes that would traverse the central region
of the tumor were acquired. On excision, the tumor was
embedded and then sectioned in the plane, matching that
of MR acquisition. Ensuring accurate spatial registration of
the tumor from in vivo to ex vivo image analysis is often
problematic. Soft tissues, in particular subcutaneous tu-
mors, 1) do not pose obvious landmarks or stereotactic co-
ordinates (unlike the brain with bregma), and 2) are not
encased in a stable framework (unlike the brain with the
cranium, or the cartilage fixed to the bone surface). One ap-
proach is to mark excised and embedded samples to orien-
tate the sectioning process [47].
Clinical studies have routinely employed noninvasive
DCE-MRI to discern the biologic and antitumor effects of
VDAs on phase I cancer patients. However, the temporal and
spatial complexity of events following VDA treatment may
necessitate multiple imaging endpoints before any conclu-
sion can be drawn about potential biologic effects (e.g.,
diffusion-weighted imaging) [42,44,48]. For example, at early
time points following VDA therapy, acute changes in vessel
perfusion and permeability are likely to predominate, where-
as at later time points, MRI measurements may be more
weighted by vascular volume changes or necrosis.
In conclusion, we have examined the relationship between
VDA-induced necrosis and multiple MRI biomarkers in the
Hras5 tumor model in rats 24 hours after treatment with clini-
cally relevant doses of ZD6126 and have found a good cor-
relation for two imaging biomarkers (EHF and nonenhancing/
nonfitted voxels) with tumor necrosis. This study provides a
preclinical rational for investigating nonenhancing voxels as
an imaging biomarker within clinical studies with potential for
noninvasive assessment of tumor necrosis.
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